Clin2
NCT07380204Worth exploringRecruiting

Measuring Hsp90 in the brain with a PET scan

Parkinson's Disease (PD)Alzheimer's Disease (AD)Amyotrophic Lateral Sclerosis (ALS)

Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.

This study uses a special PET scan to measure a protein called Hsp90 in the brain. It aims to understand how Hsp90 levels differ in healthy people and those with Parkinson's, Alzheimer's, or ALS, which may lead to new treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
48 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must be a healthy adult aged 18-70, or have Parkinson's (age 45-85), Alzheimer's (age 45-85), or ALS (age 20-85).
  • You must be able to lie still inside a PET/MRI scanner for at least 70 minutes.
  • For Parkinson's, you need a diagnosis confirmed with a DaTscan. For Alzheimer's, you need a MoCA score under 26 and amyloid evidence. For ALS, you need a possible or definite diagnosis.
  • You must avoid pregnancy or use highly effective birth control during and for a period after the study.
  • You must not have major heart, kidney, liver disease, diabetes, or most cancers. No drug or alcohol abuse allowed.
  • You must not have certain MRI contraindications like metal implants or severe claustrophobia.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06891703Recruiting· Early Phase 1
PET imaging study for Parkinson's and related conditions

This trial uses a new imaging agent (like a dye) to see signs of Parkinson's disease in the brain. If you have Parkinson's or a related condition like Lewy body dementia or multiple system atrophy, this scan may help researchers better understand these illnesses.

Solna
NCT05395624Recruiting· Phase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson

This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.

San Francisco, California
NCT07509125Recruiting
Ultra-high resolution PET brain scans for aging, dementia, and psychosis

This study uses a new ultra-high resolution PET scanner to look at brain changes in healthy aging, dementia, ALS, movement disorders, and psychosis. It aims to better understand these conditions and improve imaging techniques.

Leuven, Vlaams-Brabant
NCT06634628Recruiting· Early Phase 1
Testing a new brain scan tracer for Huntington's disease

This trial tests a new radioactive tracer called [11C]CHDI-00491009 that may show mutant huntingtin protein in the brain using a PET scan. It aims to find out if the tracer is safe and helps see Huntington's disease changes. If you have early-stage Huntington's or are a healthy volunteer, you may be able to join.

Leuven
NCT06098612Recruiting· Early Phase 1
PET imaging study for Parkinson's and related disorders

This study uses a new PET scan tracer called [11C]SY08 to take pictures of the brain in people with Parkinson's, multiple system atrophy, or dementia with Lewy bodies. It aims to see if this tracer can help better understand and tell apart these conditions.

Charlestown, Massachusetts
NCT06032026Recruiting· Early Phase 1
Brain imaging study of tracer distribution in Parkinson's and related conditions

This study uses a special imaging tracer to see how it moves through the body and brain. It may help researchers understand brain changes in Parkinson's disease and related conditions.

Philadelphia, Pennsylvania

Hear when a new Parkinson's Disease (PD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.